FOURKITES
16.6.2022 10:25:04 CEST | Business Wire | Press release
Leading real-time supply chain visibility platform FourKites® today announces it has outpaced its annual growth targets in the European, Middle Eastern and African (EMEA) markets. The company achieved 148% growth in shipments over the last 12 months, exceeding its target projections of 100% growth. The number of customers tracking loads with FourKites in EMEA has grown by 59% in the last 12 months, while the number of carriers tracking shipments has grown by 55% in the same period.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220616005418/en/
“Over the last year, we’ve invested heavily in Europe — in our team, our partners, our products and our customers. Today’s complex supply chains require global, end-to-end visibility, and the region is vital to global trade,” says FourKites CEO and founder, Mathew Elenjickal. “We’re seeing that investment reflected by our accelerated growth metrics over the last year.”
Some of FourKites’ most recent customer additions include Barilla Group, Beyond Meat, Cardinal Health, Haworth, LyondellBasell, McCain Foods, Roehm, Rove Concepts and Yamaha Motors.
Local investment pays off
In January 2022, FourKites acquired German supply chain visibility provider NIC-place , the market leader in supply chain visibility software solutions specifically designed for transport companies, carriers and logistics service providers. The acquisition created the largest multimodal carrier network in Europe, serving global shippers with the most comprehensive end-to-end global supply chain visibility platform.
In addition, over the last few months, FourKites has been investing in its local teams with seasoned industry veterans to build the infrastructure needed to support its growing European network. Recent senior-level hires include Katja van Trigt, Senior Director Talent & Development EMEA, who comes to FourKites with an enviable record having worked at American Express, Bausch & Lomb and Infoblox.
Jeroen Peijnenburg, Enterprise Account Director, Southern Europe, will lead FourKites’ supply chain visibility operations across the region. He has worked for many years in leadership positions within global, asset-owning carriers and logistics service providers.
Nicu Ciontea, Carrier Manager, based in Amsterdam, will increase carrier support across Europe. Until recently, Nicu led the carrier sales team at CH Robinson in Amsterdam.
Nicholas Mellings, Enterprise Account Director EMEA will lead FourKites’ UK Sales team. Nicholas brings with him 30 years of experience in the transport and logistics industry, the last five of which were spent working for Transporeon.
New offices
FourKites has also been growing its European presence with new offices. The company has opened a larger European headquarters in Amsterdam; a new office in Munich serving the pivotal German market; and an increased presence in Poland to serve the Eastern European carrier market.
“To support our growing network of European shippers and carriers, we have taken the steps necessary to ensure that we have a strong local presence, with highly specialised knowledge of the European market,” says Elenjickal. Elenjickal himself is currently touring in Europe, visiting the new offices, meeting face to face with customers, and personally welcoming FourKites’ new supply chain experts brought onboard to fuel organic growth.
“Europe is rapidly seizing the benefits of supply chain visibility,” he adds. “European businesses are finding that FourKites’ approach is a natural fit with their current needs, and that synergy is what’s creating more transparency, collaboration and resilience in global supply chains.”
“Digitisation is an important step in Dow’s journey toward the implementation of an end-to-end supply chain visibility strategy,” says Kevin Nielen, Logistics Leader, Dow Chemical. “Our strategic partnership with FourKites enables us to digitise and move away from a manual way of working to an integrated technology platform workflow.”
FourKites Europe in numbers
Top five countries by load volume: Belgium, France, Germany, Netherlands and Italy.
148% growth in EMEA shipments over the last 12 months
59% growth in the number of customers tracking loads in EMEA over the last 12 months
55% growth in the number of carriers tracking shipments in EMEA over the last 12 months
2.4 billion km tracked in EMEA in the last 12 months
Ports: Over the last 12 months, FourKites saw a 15% growth in the number of ports tracked in EMEA. We now cover 295 ports in the region.
Over the last 12 months, FourKites saw a 92% growth in the number of facilities tracked in EMEA. We now cover 134,000 facilities in the region.
About FourKites
Leading global supply chain visibility platform FourKites® extends visibility beyond transportation into yards, warehouses, stores and beyond. Tracking more than 2.5 million shipments daily across road, rail, ocean, air, parcel and courier, and reaching more than 200 countries, FourKites combines real-time data and powerful machine learning to help companies digitise their end-to-end supply chains. More than 1,000 of the world’s most recognised brands — including 9 of the top-10 CPG and 18 of the top-20 food and beverage companies — trust FourKites to transform their business and create more agile, efficient and sustainable supply chains. To learn more, visit https://www.fourkites.com/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005418/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
